HIV/AIDS deaths in the U.S. have dropped significantly in recent years. In 1995, the death rate from HIV per 100,000 people was 16.2. That number has since decreased to 1.3 per 100,000 as of 2023. The reduction in the HIV death rate in the U.S. can be attributed to an increase in access to HIV medications. HIV/AIDS in the U.S. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) cause a systemic viral infection that damages the immune system. AIDS is a syndrome that is caused by HIV. AIDS is when the immune system is severely weakened by HIV and the body can no longer fight off infections. Among all U.S. states, Georgia, followed by Florida and Louisiana, had the highest rates of new HIV diagnoses in 2022. HIV/AIDS treatments in the U.S. HIV/AIDS treatments include antiretroviral medications to reduce the levels of HIV within the body. The largest funders for HIV/AIDS medications and research are the National Institutes of Health (NIH) and the Ryan White Program. The top HIV drug worldwide, based on revenue generated in 2023 was Biktarvy. Around the world, access to antiretroviral treatment has increased dramatically in recent years, a huge step in reducing the number of HIV-related deaths. There is currently no cure for HIV.

This dataset contains death counts, crude rates and adjusted rates for selected causes of death by county and region. For more information, check out: http://www.health.ny.gov/statistics/vital_statistics/, or go to the "About" tab.

UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2024, the highest number of AIDS-related deaths occurred in South Africa and Mozambique and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

In 2024, South Africa and Mozambique had the highest number of deaths due to AIDS worldwide, with around ** thousand and ** thousand such deaths, respectively. African countries account for eight of the top 10 countries with the highest number of AIDS-related deaths worldwide. AIDS-related deaths worldwide have been gradually declining over the past decade, decreasing from *** million deaths in 2010 to *** thousand deaths in 2024. HIV/AIDS HIV (human immunodeficiency virus) is an infectious sexually transmitted disease that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV weakens the human immune system, resulting in the affected person being unable to fight off opportunistic infections. The top 15 countries worldwide with the highest prevalence of new HIV infections as of 2024 were all African. HIV treatment Although there is currently no effective cure for HIV, death can be prevented by taking HIV antiretroviral therapy (ART). Access to antiretroviral therapy worldwide has significantly increased in the past decade. As of 2024, around **** million people with HIV worldwide were receiving ART. The countries with the highest percentage of HIV-infected children who were receiving ART were Eswatini, Kenya, and Lesotho.

This data set includes tables on persons living with HIV/AIDS, newly diagnosed HIV cases and all cause deaths in HIV/AIDS cases by gender, age, race/ethnicity and transmission category.

In all tables, cases are reported as of December 31 of the given year, as reported by January 9, 2019, to allow a minimum of 12 months reporting delay.

Gender is determined by both current gender and sex at birth variables; transgender values are assigned when current gender is identified as "Transgender" or when a discrepancy is identified between a person's sex at birth and their current gender (e.g., cases where sex at birth is "Male" and current gender is "Female" will become Transgender: Male to Female.) Prior to 2003, Asian and Native Hawaiian/Pacific Islanders were classified as one combined group. In order to present these race/ethnicities separately, living cases recorded under this combined classification were split and redistributed according to their expected proportional population representation estimated from post-2003 data.

This dataset contains death counts and crude rates by region, age group, and selected cause of death. For more information, check out: http://www.health.ny.gov/statistics/vital_statistics/, or go to the "About" tab.

In 2023, India reported an estimate of ** thousand annual AIDS related deaths (ARD) across the country. Male deaths from HIV/AIDS amounted to nearly ** thousand, accounting for approximately ** percent of AIDS related deaths in India that year.

The AIDS Public Information Data Set (APIDS) for years 1981-2002 on CDC WONDER online database contains counts of AIDS (Acquired Immune Deficiency Syndrome) cases reported by state and local health departments, by demographics; location (region and selected metropolitan areas); case-definition; month/year and quarter-year of diagnosis, report, and death (if applicable); and HIV exposure group (risk factors for AIDS). Data are produced by the US Department of Health and Human Services (US DHHS), Public Health Service (PHS), Centers for Disease Control and Prevention (CDC), National Center for HIV, STD and TB Prevention (NCHSTP), Division of HIV/AIDS Prevention (DHP).

Introduction

• HIV (human immunodeficiency virus) is a virus that attacks the body's immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome) which currently has no cure. Once people get HIV, they have it for life. But with proper medical care, HIV can be controlled. Symptoms: Influenza-like illness; Fatigue… Treatments: Management of HIV/AIDS Type of infectious agent: Virus (Human Immunodeficiency Virus) • AIDS (acquired immune deficiency syndrome) is the name used to describe a number of potentially life-threatening infections and illnesses that happen when one’s immune system has been severely damaged by the HIV virus. While AIDS cannot be transmitted from 1 person to another, the HIV virus can.

Dataset

The data set contains data of the following:- 1. The top causes of deaths in the world 2. Total number of deaths due to HIV/AIDS 3. ART (Anti Retro-viral Therapy) coverage among people living with HIV 4. Knowledge among young citizens (15-24years) about HIV/AIDS 5. Population of HIV/AIDS patients living with TB and their death rate 6. Life expectancy rate among HIV/AIDS patients 7. HIV/AIDS Patients in different age groups 8. Women population living with HIV 9. Young women in India having the knowledge of HIV/AIDS 10. HIV/AIDS deaths in Indian states

Data was scrapped from the official website of UNICEF -https://data.unicef.org/ and https://data.gov.in/

Ask Phase

• Data gives the trend of increasing no. of HIV/AIDS patients across the world • The information available for each country is percentage of total Global AIDS patients • Time period traced is 2000-2019 • Key Questions to answer:  Which countries and regions are affected the most?  How are the different age groups affected?  How much is the ART (Anti Retro-viral Therapy) coverage among the patients and what is the life expectancy rate?  What percentage of the population is aware of the prevention and causes of HIV/AIDS

Prepare phase.

• By tabulating and filtering the data the required data was obtained to bring out observations. • Data was formatted to the desired format to perform further calculations. • Sorting of data region wise. • Columns with inconsistent and empty cells were deleted. • The data of India was extracted for further analysis • Duplicate entries and undesired data was removed

Process phase

For cleaning the dataset for further analysis MS Excel was used due to small data. • Used sumifs() functions to aggregate the data region wise • Used sumif() to segregate the no. of patients within different age groups • Used sumifs() to find the total number of TB patients among HIV deaths. • Used countif() to find the percentage of male and female patients. • Sorted data to find the top and bottom nation with most and least HIV/AIDS patients

Analyze phase

• Formed the following pivot tables to answer key target questions  Year v/s number of death rates  Country v/s death numbers to bring out nation wise deaths  Causes of death v/s the number of deaths to bring at which position AIDS causes causality  Year v/s percentage of life expectancy to observe the pattern of no. of survivors

Visualization phase

The data was visualized using Tableau.

Presentaion

The final presentation was prepared by accumulating all observations and inferences which is linked below https://docs.google.com/presentation/d/1NEX10Vz5u5Va3CrTLVbvsUHZjO-fn8EOeiOHkP03T3Q/edit?usp=sharing

In 2019, Estimated AIDS Deaths in Indonesia grew 5.3% compared to a year earlier.

Dataset refers to the Statistics Relating to Notification of HIV Aids Cases and Deaths in Mauritius for the year 2000 to 2021

Contents

HIV/AIDS** data from the HIV Surveillance Annual Report * Note: Data reported to the HIV Epidemiology and Field Services Program by June 30, 2016. All data shown are for people ages 13 and older. Borough-wide and citywide totals may include cases assigned to a borough with an unknown UHF or assigned to NYC with an unknown borough, respectively. Therefore, UHF totals may not sum to borough totals and borough totals may not sum to citywide totals."

Dataset has 18 features including:

Year, Borough, UHF, Gender, Age, Race, HIV diagnoses, HIV diagnosis rate, Concurrent diagnoses, % linked to care within 3 months, AIDS diagnoses, AIDS diagnosis rate, PLWDHI prevalence, % viral suppression, Deaths, Death rate, HIV-related death rate, Non-HIV-related death rate

In 2023, the death rate from HIV was highest among those aged 60 to 64 years, with around **** deaths per 100,000 population. This statistic shows the death rate from HIV in the U.S. in 2023, by age, per 100,000 population.

This is an extract of Causes of death since 1997 to 2012 for HIV /Aids which includes B20, B21, B22, B23, B24 (according with the ICD-10 code).

BackgroundSince the first HIV/AIDS case appeared in 1980s, HIV/AIDS has been the focus of international attention. As a major public health problem, there are epidemiological uncertainties about the future of HIV/AIDS. It is important to monitor the global statistics of HIV/AIDS prevalence, deaths, disability adjusted life years (DALYs), and risk factors for adequate prevention and control.MethodsThe Global Burden of Disease Study 2019 database was used to analyze the burden of HIV/AIDS in 1990–2019. By extracting global, regional, and national data on HIV/AIDS prevalence, deaths, and DALYs, we described the distribution by age and sex, explored the risk factors, and analyzed the trends in HIV/AIDS.ResultsIn 2019, there were 36.85 million HIV/AIDS cases (95% UI: 35.15–38.86 million), 863.84 thousand deaths (95% UI: 78.61–99.60 thousand), and 47.63 million (95% UI: 42.63–55.65 million) DALYs. The global age-standardized HIV/AIDS prevalence, death, and DALY rates were 454.32 (95% UI: 433.76–478.59), 10.72 (95% UI: 9.70–12.39), and 601.49 (95% UI: 536.16–703.92) per 100,000 cases, respectively. In 2019, the global age-standardized HIV/AIDS prevalence, death, and DALY rates increased by 307.26 (95% UI: 304.45–312.63), 4.34 (95% UI: 3.78–4.90), and 221.91 (95% UI: 204.36–239.47) per 100,000 cases, respectively, compared to 1990. Age-standardized prevalence, death, and DALY rates decreased in high sociodemographic index (SDI) areas. High age-standardized rates were observed in low sociodemographic index areas, while low age-standardized rates were observed in high sociodemographic index areas. In 2019, the high age-standardized prevalence, death, and DALY rates were predominant in Southern Sub-Saharan Africa, and global DALYs peaked in 2004 and subsequently decreased. The highest global HIV/AIDS DALYs were in the 40–44 age group. The main risk factors affecting HIV/AIDS DALY rates included behavioral risks, drug use, partner violence, and unsafe sex.ConclusionsHIV/AIDS disease burden and risk factors vary by region, sex, and age. As access to health care increases across countries and treatment for HIV/AIDS infection improves, the HIV/AIDS disease burden is concentrated in areas with low SDIs, particularly in South Africa. Regional differences should be fully considered to target optimal prevention strategies and treatment options based on risk factors.

In 2024, around ** percent of the total deaths in South Africa were acquired immunodeficiency syndrome (AIDS) related. This represented a slight decrease of *** percentage points compared to 2023. Since 2002, the share of AIDS-related deaths increased until 2006, reaching **** percent, before declining significantly. However, the number of deaths is likely to see an increase following the United States of America's decision to cut aid funding.

AIDS estimated deaths (UNAIDS estimates) in Haiti was reported at 1600 in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Haiti - AIDS estimated deaths (UNAIDS estimates) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

Forecast: Estimated AIDS Deaths in United States 2023 - 2027 Discover more data with ReportLinker!

ART not only saves lives but also gives a chance for people living with HIV/AIDS to live long lives. Without ART very few infected people survive beyond ten years.1

Today, a person living in a high-income country who started ART in their twenties can expect to live for another 46 years — that is well into their 60s.2

While the life expectancy of people living with HIV/AIDS in high-income countries has still not reached the life expectancy of the general population, we are getting closer to this goal.3

The combination of antiretroviral drugs which make-up ART have progressively improved. Recent research shows that a person who started ART in the late 1990s would be expected to live ten years less than a person who started ART in 2008.4 This increase goes beyond the general increase in life expectancy in that period and reflects the improvements in ART — fewer side effects, more people following the prescribed treatment, and more support for the people in need of ART.